EUROPEAN RESEARCH. PERSONALISED CARE.
Liver Transplantation for Colorectal Liver Metastases
A groundbreaking European research initiative seeking to redefine treatment for people with colorectal cancer and liver metastases.
Horizon Europe · Mission Cancer · 2026–2031
21
partner organisations
13
clinical sites
5 years
July 2026 – June 2031
€10M
EU funding
Key facts
According to WHO, colorectal cancer (CRC) is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases, and the second leading cause of cancer-related deaths.
The liver is the most common site of CRC metastasis, a major cause of CRC-related mortality.
Approximately 40–50% of patients with colorectal cancer develop liver metastases during the course of their disease.
The liver may be the only site of metastatic disease or one of several metastatic sites.
Surgical resection remains the standard potentially curative treatment when feasible.
For selected patients with unresectable liver-only disease, liver transplantation is emerging as a potential treatment option.
A COMPLEX QUESTION. A SHARED AMBITION.
Which treatment,
for which person?
When colorectal cancer spreads to the liver, treatment decisions can be complex. LiT-Met is investigating where liver transplantation may offer a benefit compared with complex liver resection for carefully selected patients.
LiT-Met brings clinical evidence, artificial intelligence and patient perspectives together to support more personalised decisions — and a better understanding of their long-term impact.
Understand the project →What LiT-Met is building
Europe’s largest evidence base
on liver transplantation for colorectal liver metastases
First European multicentre prospective study
comparing liver transplantation and liver resection
A multimodal platform
integrating clinical, imaging, pathological, molecular, circulating biomarker and patient-reported data
An AI-powered Clinical Decision Support System
for personalised treatment decisions
European evidence-based clinical guidelines
contributing to advanced care standards
HOW THE RESEARCH CONNECTS
From clinical evidence to everyday life.
We study not just how treatments perform, but what they mean for people and for the systems that care for them.
Learn from clinical evidence
Connect European clinical data with prospective studies to better understand treatment outcomes.
Explore more personalised decisions
Bring imaging, biological insights and AI together to investigate who may benefit from each approach.
Measure what matters
Consider survival alongside quality of life, patient priorities, equitable access and value for health systems.
July 2026
Brussels, Belgium
EU CANCER MISSION
LiT-Met at the 5 Years EU Cancer Mission conference
LiT-Met joined Europe’s cancer community in Brussels to share its multidisciplinary approach and strengthen collaboration across the EU Cancer Mission.
Coordinated by the University of Bologna, the five-year project connects clinical studies, artificial intelligence and patient perspectives.
July 2026
Bologna, Italy
PROJECT KICK-OFF
A European collaboration gets underway.
LiT-Met launched its research programme with a kick-off meeting in Bologna on 6–7 July 2026, bringing the consortium together around a shared ambition: stronger evidence for more personalised care.
Coordinated by the University of Bologna, the five-year project connects clinical studies, artificial intelligence and patient perspectives.
STRONGER TOGETHER
A European network.
A shared purpose.
21 organisations connect the expertise needed to investigate a complex clinical question.
Led by the University of Bologna, LiT-Met brings together hospitals, universities, technology specialists and organisations representing patients and healthcare professionals.
Meet the organisations behind LiT-Met →Let’s move the conversation forward.
Connect with LiT-Met for research collaboration, communication and project enquiries.